Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Reexamination Certificate
2007-08-07
2010-11-30
Bristol, Lynn (Department: 1643)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
C424S138100, C435S375000
Reexamination Certificate
active
07842293
ABSTRACT:
The present disclosure provides methods for treating multiple myeloma comprising administering to a subject with multiple myeloma the anti-CS1 antibody HuLuc63 in combination with dexamethasone and, optionally, thalidomide.
REFERENCES:
patent: 2005/0025763 (2005-02-01), Williams
patent: 2006/0024296 (2006-02-01), Williams
patent: 2005/102387 (2005-11-01), None
patent: 2008/019376 (2008-02-01), None
patent: 2008/019378 (2008-02-01), None
patent: 2008/019379 (2008-02-01), None
Yan et al. (Can. Res. 66(4):2305-2313 (2006).
Koskela et al. (Leuk. Lymphoma 45(4):749-754 (2004) Abtract.
Fundamental Immunology 242 (William E. Paul, M.D. ed., 3d ed. 1993).
ATCC search for Luc63 antibody (pp. 1-3; May 11, 2009).
Richardson et al., “A Phase 2 study of Bortezomib in relapsed,refractory myeloma,” N Engl J Med, 348:2609-2617 (Jun. 2003).
Kumar and Rajkumar, “Thalidomide and lenalidomide in the treatment of multiple myeloma,” European J Cancer, 42(2006):1612-1622, (Jul. 2006).
Tai et al., “Killing of drug-sensitive and resistant myeloma cells and disruption of their bone marrow stromal interaction by HuLuc63, a novel humanized anti-CS1 monoclonal antibody,” Blood (ASH Annual Meeting Abstracts) 2006:108: Abstract 3470 (2006).
Richardson et al., “Immunomodulatory drug CC-5013 overcomes drug resistance and is well-tolerated in patients with relapsed multiple myeloma,” Blood, 100(9):3063-3067 (Nov. 2002).
International Search Report and Written Opinion for PCT Application No. PCT/US2007/075404, dated Feb. 2, 2008.
International Search Report and Written Opinion for PCT Application No. PCT/US2007/075403, dated Jan. 16, 2008.
Tai et al., “Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu.” Blood, Oct. 9, 2007; [Epub ahead of print].
Afar et al., “Anti-myeloma activity of HuLuc63 alone and in combination with bortezomib.” Haematologica 92 (6) s2:146, 2007. (Abstract PO-530).
Rice et al., “HuLuc63 in Combination Regimens with Conventional and Targeted Therapies Has Additive and Synergistic Anti-Tumor Activity in Pre-Clinical Models of Myeloma.” Blood (ASH Annual Meeting Abstracts), Nov. 2007; 110:2517.
Sonneveld et al., “Changing concepts in multiple myeloma: from conventional chemotherapy to high-dose treatment” Eur J Cancer. Jan. 2003;39(1):9-18.
Jagannath S., “Treatment of myeloma in patients not eligible for transplantation.” Curr Treat Options Oncol. May 2005;6(3):241-53.
Bruno et al., “New drugs for treatment of multiple myeloma.” Lancet Oncol. Jul. 2004;5(7):430-42.
Lee et al., “DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma.” J Clin Oncol. Jul. 15, 2003;21(14):2732-9.
Boles et al., “Molecular cloning of CS1, a novel human natural killer cell receptor belonging to the CD2 subset of the immunoglobulin superfamily.” Immunogenetics. 2001;52(3-4):302-7.
International Search Report and Written Opinion for PCT Application No. PCT/US2007/075401, dated May 15, 2008.
Anderson, Kenneth C., Lenalidomide and Thalidomide: Mechanisms of Action—Similarities and Differences,Seminars in Hematology, vol. 42, pp. S3-S8 (2005).
Bray et al., “Studies on the Mechanism of Human Natural Killer Cell-Mediated Cytolysis,”Cellular Immunology, vol. 78, pp. 100-113 (1983).
Cavo et al., “Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma,”Blood, vol. 106, pp. 35-39 (2005).
Liu et al., “Chimeric mouse-human IgG1 antibody that can mediate lysis of cancer cells,”Proc. Natl. Acad. Sci., vol. 84, pp. 3439-3443 (1987).
Piccolella et al., Effects of Dexamethasone on Human Natural Killer Cell Cytotoxicity, Interferon Production, and Interleukin-2 Receptor Expression Induced by Microbial Antigens,Infection and Immunity, vol. 51, No. 2, pp. 712-714 (1986).
Bristol Lynn
Dechert LLP
Facet Biotech Corporation
LandOfFree
Compositions and methods using anti-CS1 antibodies to treat... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods using anti-CS1 antibodies to treat..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods using anti-CS1 antibodies to treat... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4227449